ETHZilla Rebrands to Forum Markets, Aiming to Revolutionize Digital Asset Integration
- ETHZilla has rebranded as Forum Markets, focusing on integrating digital assets with traditional capital markets.
- Forum Markets will trade on Nasdaq under ticker symbol “FRMM,” pending regulatory approval by March 2026.
- The rebrand emphasizes institutional-grade, on-chain financial products and aims to enhance access to digital asset markets.
ETHZilla Rebrands as Forum Markets, Embarking on a New Digital Asset Journey
ETHZilla Corporation has officially rebranded itself as Forum Markets, Incorporated, marking a significant shift in the company’s strategy towards integrating digital assets with traditional capital markets. Set to trade on The Nasdaq Capital Market under the new ticker symbol “FRMM” starting March 2, 2026, pending regulatory approval, this transformation underscores Forum's ambition to enhance financial infrastructure in a rapidly evolving market. Since its inception in August 2025, the company has focused on building the necessary backbone to support digital transactions, positioning itself as a leader in the tokenization of real-world assets.
Central to Forum's new identity is the integration of blockchain technology in financial transactions, putting it at the forefront of a revolution in capital markets. CEO McAndrew Rudisill announces that the rebranding symbolizes an evolution toward becoming a next-generation marketplace. This platform aims to connect institutional capital with cash-generating assets that have traditionally been available only to large institutions. By focusing on transparency and governance, Forum is redefining the accessibility and management of these assets, ensuring that institutional investors can engage with blockchain-backed financial products that maintain a high standard of compliance and trust.
Moreover, Forum Markets has already established partnerships and distributed its assets through channels like Liquidity.io. The company has also invested in innovative AI-driven platforms to enhance credit and underwriting processes, thereby opening doors to diverse asset pools, including auto loans and manufactured housing finance. Senior vice president John Kristoff emphasizes a deliberate pivot from merely holding Ethereum; instead, the focus now lies in leveraging its capabilities to create sustainable products in a secure marketplace. This marks a pivotal moment not just for Forum Markets but for the broader digital asset industry, aiming to create a more inclusive financial ecosystem that caters to a range of investors.
In addition to its rebranding, Forum Markets is setting itself apart by emphasizing institutional-grade, on-chain financial products. As the company works to aggregate and tokenize these high-quality assets, it offers significant value to both asset originators and institutional investors. This strategic direction represents a move away from traditional finance, addressing evolving market needs while fostering advancements in digital asset management.
Overall, Forum's commitment to enhancing compliance and innovating market infrastructure establishes it as a vital player in the intersection of traditional finance and blockchain opportunities. The rebranding signals a promising future for the company and a potential shift in how institutional investors engage with digital assets.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…